Literature DB >> 33533509

Meropenem use and therapeutic drug monitoring in clinical practice: a literature review.

Nadine A Steffens1, Estevan S Zimmermann2, Sabrina M Nichelle3, Natália Brucker1,3.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Meropenem, a carbapenem antibiotic, is widely prescribed for the treatment of life-threatening infections. The main parameter associated with its therapeutic success is the percentage of time that the levels remain above the minimum inhibitory concentration. Inadequate levels of meropenem can lead to therapeutic failure and increase the possibility of microbial resistance. The employment of strategies involving dose regimens and drug pharmacodynamics has become increasingly important to optimize therapies. In the present study, we conducted a review with the purpose of assembling information about the clinical use of meropenem and therapeutic drug monitoring.
METHODS: A literature review emphasizing the application of therapeutic drug monitoring (TDM) of meropenem in clinical practice has been done. To identify articles related to the topic, we performed a standardized search from January 21, 2020 to December 21, 2020, using specific descriptors in PubMed, Lilacs and Embase. RESULTS AND DISCUSSION: In total, 35 studies were included in the review. The daily dose of meropenem commonly ranged from 3 to 6 g/day. Critically ill patients and those with impaired renal function appear to be the most suitable patients for the application of meropenem TDM, in order to guide therapy. We observed that most of the studies recommend TDM and that, in nine locations, the TDM of meropenem and of other beta-lactams is a routine practice. TDM data can help to maximize the clinical outcomes of the treatment with meropenem. It can also improve the patient care by providing suitable levels of meropenem, guiding the most appropriate dose regimens, which is the main parameter associated with therapeutic success. WHAT IS NEW AND
CONCLUSION: The findings from this review suggest that the therapeutic monitoring of meropenem can be beneficial, since it adjusts the treatment and aids clinical outcomes. It does so by indicating the appropriate dosage and preventing failure, toxicity and possible antimicrobial resistance. The multidisciplinary effort, basic knowledge and communication among the medical team are also essential.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  TDM; antibiotics; clinical practice; infection

Mesh:

Substances:

Year:  2021        PMID: 33533509     DOI: 10.1111/jcpt.13369

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

1.  Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa.

Authors:  A Nussbaumer-Pröll; S Eberl; E Kurdina; L Schmidt; M Zeitlinger
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.810

2.  Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia.

Authors:  Abdullah Alsultan; Shereen A Dasuqi; Fadi Aljamaan; Rasha A Omran; Saeed Ali Syed; Turki AlJaloud; Abdullah AlAhmadi; Saeed Alqahtani; Mohammed A Hamad
Journal:  Saudi Pharm J       Date:  2021-10-08       Impact factor: 4.330

Review 3.  Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.

Authors:  Engy Elekhnawy; Walaa A Negm; Suzy A El-Sherbeni; Ahmed Zayed
Journal:  Inflammopharmacology       Date:  2022-08-26       Impact factor: 5.093

4.  Multiple Secondary Healthcare-Associated Infections Due to Carbapenem-Resistant Organisms in a Critically Ill COVID-19 Patient on Extensively Prolonged Venovenous Extracorporeal Membrane Oxygenation Support-A Case Report.

Authors:  Hiroaki Baba; Hajime Kanamori; Issei Seike; Ikumi Niitsuma-Sugaya; Kentaro Takei; Kengo Oshima; Yudai Iwasaki; Yuko Ogata; Hirona Nishimaki; Daisuke Konno; Takuya Shiga; Koji Saito; Koichi Tokuda; Tetsuji Aoyagi
Journal:  Microorganisms       Date:  2021-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.